Oxford PharmaGenesis creates new Director of Innovation role and makes first appointments

14 May 2021

Share this page

Share this page on LinkedIn

Oxford PharmaGenesis has made its first appointments to the new role of Director of Innovation, created specifically to support teams across the global organization in utilizing new and emerging technology to support their clients’ unmet needs.

Dr Tomas Rees moves from his previous role as Communications Director, while Dr Martin Callaghan was previously Director of Digital Communications – roles Tom and Martin have held since joining the company in 2018. Tom has supported multiple global clients in pioneering the development of novel approaches to assessing the impact of medical communications, and developing Oxford PharmaGenesis’ proprietary PubsPro methodology. Martin has transformed the company’s digital capabilities, building a team that provides class-leading offerings in e-learning, interactive web applications and data visualization. Martin also led development of the highly successful QRdb, an easy-to-use and impactful app for distributing congress materials and their supplementary content to healthcare professionals via live and virtual congresses.

“We have created the Director of Innovation role to ensure that Oxford PharmaGenesis continues to provide field-leading offerings to our clients across our global organization,” said Dr Richard White, Chief Operating Officer at Oxford PharmaGenesis. “I am delighted that, in Martin and Tom, we are able to appoint to this role two of the most creative thinkers and doers in our sector, who have both already demonstrated their ability to create new products and services that our clients love. I am excited at the opportunities this will bring for our clients and our company in the future.”

Tom and Martin will focus initially on several ongoing projects, including utilizing AI-based tools for data analysis and communication, developing conversational experiences, and understanding how gameplay influences learning and behaviour. For more information on our innovative capabilities, contact us here.